These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Clinical experience with guanfacine in long-term treatment of hypertension. Part II: adverse reactions to guanfacine.
    Author: Jerie P.
    Journal: Br J Clin Pharmacol; 1980; 10 Suppl 1(Suppl 1):157S-164S. PubMed ID: 6994770.
    Abstract:
    1 In 580 hypertensive patients treated with guanfacine for one year and 169 patients who continued the treatment for a second year, laboratory measurements were made before, during and after the end of treatment. Side-effects were registered every month. On completion of the one and two-year studies respectively, therapy was discontinued and blood pressure, heart rate and side-effects were recorded in order to assess the frequency of a withdrawal syndrome. 2 No impairment of laboratory values was seen during long-term treatment. There was no retention of sodium, chloride and water, and no potassium depletion. Guanfacine did not interfere with carbohydrate metabolism during the long-term treatment, and there was no deterioration of clinical diabetes. 3 The overall frequencies of dryness of the mouth and sedation were 60 and 33%, respectively. At the end of one year of treatment these figures dropped to 15 and 5.7%. Further untoward reactions in the first and second year, respectively, were orthostatic disturbances (15 and 6.5%), constipation (14 and 4.1%), male sexual dysfunction (4.6 and 0.6%), insomnia (5.5 and 2.2%), and sweating (5.3 and 1.7%). 4 The frequency and severity of side-effects were dose dependent and related to increases in dosage. Doses of 2 mg and lower caused practically no dryness of the mouth. 5 A withdrawal syndrome occurred in about 3% of patients after discontinuation of prolonged treatment. It was seen in patients with a history of very high blood pressure readings, who showed a tendency to tachycardia and who had been treated with divided doses of guanfacine exceeding 4 mg daily. 6 Only patients with clinical symptoms of increased sympathetic activity were considered to have a withdrawal syndrome (or `phenomenon'). 7 No signs of tachyphylaxis or habituation (tolerance) were seen during the long-term treatment with guanfacine.
    [Abstract] [Full Text] [Related] [New Search]